Thus, stable expression of wild type p53 rescues the defects in mitosis, proliferation, and tumorigenesis in MM cells and enhances the therapeutic effect of BTZ both in vitro and in vivo. The gene discussed is TP53; the disease is Miyoshi myopathy.